Jay Olson Recent News
Portola Pharmaceuticals: Expect Additional Upside From Here
FDA Expresses Concern On TherapeuticsMD; Oppenheimer Downgrades
The Bull-Bear Debate In Therapeutics Rages From Research Notes To Twitter
Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside
Why Goldman Is Still Selling Mannkind
Goldman Downgrades Portola Pharma To Neutral, Removes From Buy List
MannKind's Short Interest Has 'Grown High,' Analyst Says